| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3456 | 2017 |
| Genomic hallmarks of localized, non-indolent prostate cancer M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ... Nature 541 (7637), 359-364, 2017 | 653 | 2017 |
| PCA3: a molecular urine assay for predicting prostate biopsy outcome IL Deras, SMJ Aubin, A Blase, JR Day, S Koo, AW Partin, WJ Ellis, ... The Journal of urology 179 (4), 1587-1592, 2008 | 634 | 2008 |
| PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy LS Marks, Y Fradet, IL Deras, A Blase, J Mathis, SMJ Aubin, AT Cancio, ... Urology 69 (3), 532-535, 2007 | 604 | 2007 |
| Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers VB Lokeshwar, T Habuchi, HB Grossman, WM Murphy, SH Hautmann, ... Urology 66 (6), 35-63, 2005 | 588 | 2005 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 547 | 2021 |
| PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: associations with localized stage progression BA Inman, TJ Sebo, X Frigola, H Dong, EJ Bergstralh, I Frank, Y Fradet, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 546 | 2007 |
| Photodynamic diagnosis of non–muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data M Burger, HB Grossman, M Droller, J Schmidbauer, G Hermann, ... European urology 64 (5), 846-854, 2013 | 519 | 2013 |
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ... Annals of Oncology 30 (6), 970-976, 2019 | 465 | 2019 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 461 | 2020 |
| Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA SA Tomlins, SMJ Aubin, J Siddiqui, RJ Lonigro, L Sefton-Miller, S Miick, ... Science translational medicine 3 (94), 94ra72-94ra72, 2011 | 441 | 2011 |
| Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes RK Lee, H Abol‐Enein, W Artibani, B Bochner, G Dalbagni, ... Wiley Periodicals, Inc., 2014 | 419 | 2014 |
| Widespread and functional RNA circularization in localized prostate cancer S Chen, V Huang, X Xu, J Livingstone, F Soares, J Jeon, Y Zeng, JT Hua, ... Cell 176 (4), 831-843. e22, 2019 | 389 | 2019 |
| Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma ME Gleave, M Elhilali, Y Fradet, I Davis, P Venner, F Saad, LH Klotz, ... New England Journal of Medicine 338 (18), 1265-1271, 1998 | 383 | 1998 |
| A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III … Y Fradet, HB Grossman, L Gomella, S Lerner, M Cookson, D Albala, ... The Journal of urology 178 (1), 68-73, 2007 | 362 | 2007 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 360 | 2014 |
| Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy … JC Nickel, Y Fradet, RC Boake, PJ Pommerville, JP Perreault, SK Afridi, ... CMAJ: Canadian Medical Association Journal 155 (9), 1251, 1996 | 356 | 1996 |
| Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer A Stenzl, M Burger, Y Fradet, LA Mynderse, MS Soloway, JA Witjes, ... The Journal of urology 184 (5), 1907-1914, 2010 | 352 | 2010 |
| A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with … HB Grossman, L Gomella, Y Fradet, A Morales, J Presti, C Ritenour, ... The Journal of urology 178 (1), 62-67, 2007 | 350 | 2007 |
| Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Y Fradet, C Cordon-Cardo, T Thomson, ME Daly, WF Whitmore Jr, ... Proceedings of the National Academy of Sciences 81 (1), 224-228, 1984 | 342 | 1984 |